{"altmetric_id":20561882,"counts":{"readers":{"mendeley":9,"citeulike":0,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["Giorgio Bolis","Giovanna Scarfone","Gianpiero Polverino","Francesco Raspagliesi","Saverio Tateo","Giovanni Richiardi","Mauro Melpignano","Massimo Franchi","Giorgia Mangili","Mauro Presti","Antonella Villa","Enrico Conta","Paolo Guarnerio","Sonia Cipriani","Fabio Parazzini"],"doi":"10.1200\/jco.2004.03.017","first_seen_on":"2017-05-26T10:57:10+00:00","handles":[],"isbns":[],"issns":["0732-183X","1527-7755"],"issue":"4","journal":"Journal of Clinical Oncology","last_mentioned_on":1380240000,"links":["http:\/\/dx.doi.org\/10.1200\/JCO.2004.03.017"],"pmid":"14966092","pubdate":"2004-02-15T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer: A Randomized Trial","type":"article","volume":"22","mendeley_url":"http:\/\/www.mendeley.com\/research\/paclitaxel-175-225-mg-per-meters-squared-carboplatin-advanced-ovarian-cancer-randomized-trial"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":7792430,"mean":6.6312338178446,"rank":1906454,"this_scored_higher_than_pct":61,"this_scored_higher_than":4820795,"rank_type":"exact","sample_size":7792430,"percentile":61},"similar_age_3m":{"total_number_of_other_articles":99716,"mean":11.13435418944,"rank":29385,"this_scored_higher_than_pct":69,"this_scored_higher_than":69421,"rank_type":"exact","sample_size":99716,"percentile":69},"this_journal":{"total_number_of_other_articles":8212,"mean":13.456853489222,"rank":4020,"this_scored_higher_than_pct":35,"this_scored_higher_than":2952,"rank_type":"exact","sample_size":8212,"percentile":35},"similar_age_this_journal_3m":{"total_number_of_other_articles":98,"mean":35.498639175258,"rank":79,"this_scored_higher_than_pct":19,"this_scored_higher_than":19,"rank_type":"exact","sample_size":98,"percentile":19}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":1,"Researcher":1,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":1,"Student  > Master":1,"Other":2,"Professor":1},"by_discipline":{"Medicine and Dentistry":6,"Biochemistry, Genetics and Molecular Biology":2,"Unspecified":1}}},"geo":{"mendeley":{"GB":1}}},"posts":{"policy":[{"title":"Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer: Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/TA284\/documents\/ovarian-cancer-topotecan-pegylated-liposomal-doxorubicin-hydrochloride-paclitaxel-trabectedin-and-gemcitabine-for-advanced-recurrent-disease-only-review-of-ta-91-ta-222-evaluation-report2","license":"public","citation_ids":[20561680,1136659,6275356,1728416,20561687,20561690,5772760,541709,4042751,20561692,20561693,20561696,20561698,20561700,4042788,2343551,2415007,457633,20561702,4042776,400922,226395,20561703,20561704,20561706,20561708,5370385,4042734,18183496,17905315,20561711,20561713,5788174,20561719,17913691,20561722,17923764,7419154,4042808,20560301,18183338,17910761,4042805,5557956,228533,5947914,18183333,20561743,20561748,7031810,18183385,4042765,20561753,17902114,17970611,20561757,20561763,20561767,4042814,8230792,20561785,18183366,17988925,20561791,20561795,17919340,20561801,6068244,16865381,629291,20561810,5823545,20561820,20561835,17960683,16018866,611063,20561842,481769,9970789,819044,653216,4042809,441586,20561852,13046236,20561854,13252948,18257390,20561858,20561860,6091441,20561865,20561866,20561875,17908190,20561882,20561884,12874282,723389,20561895,20561898,727227,20561903,20561911,109728,1448836,1448836],"posted_on":"2013-09-27T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta284\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-b84baa077e9382c47bdb9e8db5737bf0bdee5bdd8a2fcf2f66e143c475d1b5d4.jpg"}}]}}